CORRECTION: Sublimity To Present at Three Life science Investment Conferences
27.2.2020 12:51:04 CET | GlobeNewswire by notified | Press release
SOLANA BEACH, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday,February 27th by Sublimity Therapeutics, please note that in the last contact information, Bob Butler's email address should be bob.butler@sublimitytherapeutics.com, not bob.butler@sublimitytherapeutics.co. The corrected release follows:
Sublimity Therapeutics, a biopharmaceutical company focused on creating meaningful new treatments for GI and immunological diseases, today announced that the company will present at three upcoming conferences in March and April: Cowen & Co. Annual Healthcare Conference 2020, Solebury Trout Spring Private Company Showcase 2020, and The 19th Annual Needham Healthcare Conference.
The company’s primary focus is its Phase 2b clinical trial, CYC-202/The AURORA Study. This multicenter, randomized, double-blind, placebo-controlled, parallel-group study is intended to evaluate the safety, efficacy and tolerability of the company’s lead drug candidate, ST-0529, for patients with moderate to severe ulcerative colitis.
Cowen & Co. Annual Healthcare Conference 2020
Tuesday, March 3, 2020 at 4:00 pm ET in Boston, MA
Albert Agro, PhD, Sublimity’s President and CEO, will present
Solebury Trout Spring Private Company Showcase 2020
Thursday, April 2, 2020 in New York, NY
Ross Maclean, PhD, Sublimity’s Chief Regulatory Officer and EVP Translational Medicine, will present
The 19th Annual Needham Healthcare Conference
Tuesday, April 14, 2020 in New York, NY
Ross Maclean, PhD, Sublimity’s Chief Regulatory Officer and EVP Translational Medicine, will present
About Sublimity Therapeutics
Sublimity Therapeutics, a clinical-stage biopharmaceutical company with offices in Dublin, Ireland, and Solana Beach, California, is dedicated to identifying and creating meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases. The company’s lead program, ST-0529, an orally delivered topical formulation of cyclosporine for moderate to severe ulcerative colitis, is in Phase 2 clinical development. ST-0529 utilizes Sublimity’s proprietary Single-Multiple Pill (SmPill®) technology, a versatile delivery system for solubilizing active therapeutic agents. This technology has broad applications for drugs with poor solubility, poor gastrointestinal permeability, a propensity for degradation in the stomach and by heat, or suboptimal pharmacokinetics. It also provides an avenue to deliver API directly to the gut with a targeted, local approach. This technology has enabled Sublimity to advance a diverse pipeline of oral small molecules that have the potential to make important contributions to human health. For more information, visit: www.sublimitytherapeutics.com
About Ulcerative Colitis
It is estimated that ulcerative colitis affects approximately 1.7 million patients in North America, Europe and other developed countries. The mainstays of treatment for this disease are anti-TNFs; however, these drugs are limited by their toxicities and safety liabilities. A large portion of patients are either unresponsive to initial front-line anti-TNF therapy or become refractory to treatment within the first year. Despite the introduction of new medicines, these patients still have significant unmet medical needs.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements under applicable securities laws. Such forward-looking statements involve and are subject to substantial risks and uncertainties. The company has tried, wherever possible, to identify such statements by using words such as “will,” “may,” “could,” “anticipate,” “estimate,” “intend,” “target,” and other words and terms of similar meaning or by using future dates in connection with any discussion thereof. Statements expressed or implied concerning future actions, conditions or events, future operating results, are forward-looking statements. The company cannot guarantee that any forward-looking statement will be realized, and you are cautioned not to put undue reliance on such forward-looking statements. The company undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
CONTACT INFORMATION:
| Investors: Albert Agro President & CEO Sublimity Therapeutics Ph: +1-858-952-2577 albert.agro@sublimitytherapeutics.com | Media: Bob Butler VP Corporate Communications & Strategic Partnerships Sublimity Therapeutics Ph: +1-902-240-2250 bob.butler@sublimitytherapeutics.com |
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release
Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a
DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release
Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68
Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release
Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email verdbrefamidlun@landsbankinn.is.
Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release
AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us
Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release
VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin